- Home
- HBCP vs AUTL Comparison
HBCP vs AUTL Comparison
Compare HBCP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBCP | AUTL |
|---|---|---|
| Founded | 1908 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 433.8M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HBCP | AUTL |
|---|---|---|
| Price | $63.04 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $63.50 | $8.33 |
| AVG Volume (30 Days) | 37.8K | ★ 2.1M |
| Earning Date | 01-26-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 29.01 | N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | ★ $148,656,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $672.42 |
| Revenue Next Year | $9.09 | $84.48 |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | 12.31 | ★ 406.67 |
| 52 Week Low | $39.59 | $1.11 |
| 52 Week High | $64.17 | $2.70 |
Technical Indicators
Market Signals| Indicator | HBCP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 40.18 |
| Support Level | $61.56 | $1.31 |
| Resistance Level | $63.37 | $1.45 |
| Average True Range (ATR) | 1.93 | 0.07 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 71.06 | 18.37 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.